Intas Laboratories Pvt. Ltd. And Anr. v.Novaritis A.G., Schwarzwaldallee,
Madras High Court · O.A.No. 13/2004 and A.No. 1218 of 2004 in C.S.No. 5 of 2004; O.A.No. 14 of 2004 & A.No. 1076 of 2004 in C.S.No. 6 of 2004; O.A.No. 15 of 2004 and A.Nos. 841, 842 and 843 of 2004 in C.S.No. 7 of 2004; O.A.No. 16 of 2004 and A.Nos. 844, 845 and 846 of 2004
The dispute concerned the validity of an Exclusive Marketing Right (EMR) granted to Novaritis for the anti-cancer drug, Beta-Crystalline form of Imatinib Mesylate. Intas Laboratories challenged this EMR, arguing it created a monopoly and harmed public interest due to high pricing. The Madras High Court confirmed the interim injunction but mandated that the plaintiffs supply the drug freely to eligible patients.
